Almirall acquires rights to Veltin and Altabax from Stiefel in exchange for its rights to Toctino.

Almirall, the global pharmaceutical company based in Barcelona, announces the acquisition of the rights to two Dermatology products, Veltin and Altabax, from Stiefel, a GSK company in exchange for distribution rights to Toctino and an undisclosed cash payment. In June 2010, Almirall and Basilea Pharmaceutica Ltd signed a distribution agreement for Toctino, granting Almirall commercialisation rights in selected European markets and Mexico. Stiefel acquired worldwide rights to Toctino in June 2012 from Basilea, and has now consolidated rights to Toctino in Europe. Altabax is a patent protected and novel topical treatment for Impetigo, a highly contagious and the most common bacteria infection in children. Veltin is a prescription antibiotic indicated for the topical treatment of acne, the largest Dermatology indication in the US with a total market size of approximately $3 billion. Both Veltin� and Altabax� will be commercialised through Almirall's US affiliate, Aqua Pharmaceuticals. This strategic acquisition reinforces Almirall's Dermatology franchise in the U.S. and the international expansion of the group.